The majority of stroke results from focal brain infarction, followed by substantial secondary excitotoxic damage in the surrounding areas. Tau has been shown to contribute to excitotoxicity and neurodegeneration in mouse models of Alzheimer’s disease (AD). Preliminary data show that tau reduction also protects against excitotoxic damage after experimental stroke. We aim to dissect the molecular mechanisms of stroke using a tau-deficient mouse model.
A New Animal Model Of The Prodrome In Schizophrenia. Enhanced Dopamine In Prodromal Schizophrenia (EDiPs)
Funder
National Health and Medical Research Council
Funding Amount
$571,990.00
Summary
Psychiatrists now recognize a pre-symptomatic stage is present in people at risk of developing schizophrenia. Using new brain imaging techniques we now know that some of these individuals have changes in a major neurotransmitter, dopamine, prior to being diagnosed. We have developed a new model in animals, which recreates these exact same changes at a comparable age. We want to now understand what are the broader effects in the brain and try and block these changes in dopamine with new drugs.
Neuroprotection Against Parkinson’s Disease With Remote Photobiomodulation
Funder
National Health and Medical Research Council
Funding Amount
$314,818.00
Summary
Treating the head of rodents with low-intensity 670nm light protects against Parkinson’s disease (PD), but the large size of the human skull and brain precludes clinical translation of this treatment. We have discovered that the brain is also protected when light is targeted at peripheral tissues (e.g. a limb), overcoming problems of delivery. This project aims to optimise this treatment and better understand how it works, to lay the scientific basis for a clinical trial.
This Project will produce the first map of the brain mechanisms that motivate unhealthy food choices in obesity. This outcome can inform the development of novel treatment approaches for obesity that modify the preference for high-calorie, unhealthy foods by changing the neural bases of such preferences.
Dopamine Neuron Ontogeny: Convergent Neurobiological Pathway For Risk Factors Of Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$337,214.00
Summary
Schizophrenia is associated with changes in dopamine (a signalling molecule in the brain). These changes are present prior to psychosis, suggesting they begin early in development. Our aims are to manipulate key factors in the development of brain dopamine systems to clarify their role in psychosis and schizophrenia. This work has the potential to identify early brain changes that lead to schizophrenia, which in turn may generate better diagnoses and outcomes for people with this disorder.
This is an application for reappointment as a Principal Research Fellow. My primary area of research is preclinical studies of addiction, with a particular emphasis on relapse. I am increasingly engaged in translational studies.
The Developmental Vitamin D-deficiency Animal Model Of Schizophrenia:- Critical Window For Intervention And Optimal Dose
Funder
National Health and Medical Research Council
Funding Amount
$365,811.00
Summary
We have established that low levels of vitamin D at birth increase the risk of children developing schizophrenia in later life. Our studies indicate this risk is dose-dependent and may be enhanced if developmental vitamin D (DVD) deficiency is extended into postnatal life implying there may be an early critical vitamin D threshold and a critical window of exposure required to avert schizophrenia. This project will examine this and the effects of supplements using our DVD-deficiency animal model.
Maternal Vitamin D Supplementation In A Maternal Immune Activation Model Of Schizophrenia: Mechanisms Of Prevention
Funder
National Health and Medical Research Council
Funding Amount
$523,364.00
Summary
Maternal infection and vitamin D deficiency during pregnancy increase the risk of children developing schizophrenia. We model these risk factors in pregnant mice. Offspring produce schizophrenia-like behaviours. When pregnant mice with experimental inflammation are treated with the hormonally active form of vitamin D this completely abolished all schizophrenia-like behaviours in offspring. We want to a) understand this mechanism, b) replicate using a form of vitamin D safe-to-use in humans.
Anxiety and addiction are disorders with high co-morbidity that present a major worldwide public health concern. Treatment in both cases often involves an approach called extinction which helps to reduce the relapsing nature of these disorders. This grant is designed to examine the role of a specific protein in addiction and anxiety, by virtue of its involvement in the process of extinction.